Site-specific survival analyses revealed a significantly worse 5-year (p = 0.013) and 3-year (p = 0.004) OS and 3-year progression-free interval (p = 0.043) in patients with laryngeal cancer and low tumor TSPO expression, whereas no other site-specific associations were found (Supplementary Figure S5). This evidence concerns the gene TSPO and laryngeal carcinoma.